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Abstract 
With advances in drug treatment of breast cancer, the number of patients experiencing 
cardiac toxicity or carcinomatous pericarditis is expected to increase. These conditions can 
cause cardiac tamponade, which is a potentially fatal condition requiring prompt diagnosis 
and treatment. We experienced 3 breast cancer patients with cardiac tamponade due to 
carcinomatous pericarditis who survived for prolonged periods after treatment with 
pericardiocentesis and intrapericardial instillation. The 3 women were 68, 46 and 46 years 
old, respectively, and receiving treatment for recurrent breast cancer after surgery. They 
developed dyspnea and cough and were diagnosed with cardiac tamponade by 
echocardiography. Pericardiocentesis was performed, and cytology of the effusion 
confirmed the diagnosis of carcinomatous pericarditis. Intrapericardial instillation of cisplatin 
reduced the cardiac effusion, ameliorating symptoms. The patients died 13, 31 and 14 
months later, respectively. In our clinical review of 13 other cases of cardiac tamponade due 
to breast cancer, 85% achieved local control after the aforementioned local treatments, 
which were considered to be effective. Although the overall prognosis was poor with a 
median survival time of only 4 months, some patients were able to survive more than 1 year 
after local treatment with subsequent systemic therapy. 
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Introduction 
Recent developments in molecular targeting agents and new anticancer drugs have 
contributed to dramatic improvements in the life expectancy of patients with recurrent 
breast cancer [1, 2]. With the prolongation of survival, long-term treatment for 
recurrent cancer has become more frequent and the importance of systemic 
management has increasingly been recognized. It is particularly expected that the 
occurrence of cardiac tamponade due to cardiac toxicity associated with the use of 
molecular targeting agents or carcinomatous pericarditis will increase. Therefore, it is 
important to assure early diagnosis and appropriate treatment of heart failure in these 
patients [3]. We experienced 3 breast cancer patients with cardiac tamponade due to 
carcinomatous pericarditis who survived for a prolonged period after treatment with 
pericardiocentesis and intrapericardial instillation of cisplatin (CDDP). We 
retrospectively reviewed therapeutic outcomes of our patients, including 13 additional 
patients, who developed cardiac tamponade, to determine the usefulness of 
pericardiocentesis for carcinomatous pericarditis. 
Case Reports 
Case 1 
A 60-year-old woman underwent breast-conserving surgery and sentinel lymph node biopsy for 
left breast cancer. Histological examination showed a scirrhous carcinoma 1.6 cm in diameter (n0, ER 
positive, PgR positive and HER2 negative). Postoperative radiotherapy and tamoxifen were 
administered as adjuvant therapy. Four years and 8 months after surgery, she developed 
carcinomatous pleurisy, for which anastrozole treatment was started. After that, she had hepatic 
metastasis and peritoneal dissemination, for which capecitabine, paclitaxel and irinotecan were 
administered. Seven years and 9 months after surgery, when she was 68 years old, the patient 
developed dyspnea, and the presence of pericardial effusion was confirmed by echocardiography. 
Diuretics were administered but the symptoms worsened, and the patient was admitted to the 
hospital. 
At the time of admission, her blood pressure was 107/70 mm Hg, pulse rate 84/min and SpO2 97% 
(room air). Chest X-ray showed an enlarged heart shadow (fig. 1a) and chest CT showed pericardial 
effusion (1.6 cm) and right pleural effusion (fig. 1b). Echocardiography revealed pericardial effusion 
and collapse of the right heart (fig. 1c), so cardiac tamponade was diagnosed. Pericardiocentesis was 
performed and a drainage tube was placed. Bloody pericardial fluid was drained, and the cytology was 
interpreted as class V. CDDP 10 mg was administered into the pericardial cavity on the 3rd hospital 
day, and the drainage tube was removed on the 4th hospital day. After discharge, the patient showed 
improvements in her activities of daily living (ADL) and restarted irinotecan. She then developed 
carcinomatous peritonitis, for which CDDP was administered into the abdominal cavity. Eight years 
and 10 months after surgery, the patient died (1 year and 1 month after the onset of cardiac 
tamponade). 
Case 2 
A 33-year-old woman underwent mastectomy of the right breast and axillary lymph node 
dissection for right breast cancer. Then, she underwent mastectomy of the left breast and axillary 
lymph node dissection for left breast cancer at age 38 years. Histological examination showed a solid-
tubular carcinoma 4.0 cm in diameter (n1, ER negative, PgR positive and HER2 negative). 
Postoperative adjuvant treatment with tamoxifen and doxifluridine was administered. Lung 
metastasis was found 5 years and 5 months after surgery, for which CMF (cyclophosphamide + 
methotrexate + fluorouracil) and anastrozole were administered. Seven years and 5 months after 
surgery, when she was 46 years old, she developed cough and dyspnea. Chest CT showed pericardial 
effusion (2 cm) and multiple lung metastases. The patient was diagnosed with cardiac tamponade by 
echocardiography and admitted to the hospital.  
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Pericardiocentesis was performed and a drainage tube was placed. Bloody pericardial fluid was 
drained, and the cytology was interpreted as class V. CDDP 10 mg was administered into the 
pericardial cavity on the 2nd hospital day, and the drainage tube was removed on the 4th hospital 
day. After discharge, the patient showed improvements in her ADL and started exemestane. She then 
developed lung metastases, for which capecitabine was administered. She also developed brain 
metastasis, for which tumorectomy and whole-brain radiation were performed. Ten years after 
surgery for left breast cancer, the patient died (2 years and 7 months after the onset of cardiac 
tamponade). 
Case 3 
A 39-year-old woman underwent mastectomy and axillary lymph node dissection for left breast 
cancer. Histological examination showed a scirrhous carcinoma 2.5 cm in diameter (n1, ER positive, 
PgR positive and HER2 negative). Postoperative adjuvant treatment with tamoxifen and an LH-RH 
agonist was administered. Six years and 6 months after surgery, she developed a cervical lymph node 
recurrence, for which an LH-RH agonist and docetaxel were administered. Nine years and 7 months 
after surgery, when she was 46 years old, she developed dyspnea, and pericardial effusion (1.1 cm) 
and right pleural effusion were confirmed by echocardiography. The patient was admitted to the 
hospital with a diagnosis of cardiac tamponade. 
Pericardiocentesis was performed and a drainage tube was placed. The cytology was interpreted 
as class IIIb. Carcinomatous pericarditis was strongly suspected from the clinical course. CDDP 10 mg 
was administered into the pericardial cavity on the 5th hospital day, and the drainage tube was 
removed on the 7th hospital day. After discharge, the patient showed improvements in her ADL and 
started EC (epirubicin + cyclophosphamide). She had an exacerbation of the cervical lymph node 
metastasis, for which capecitabine was administered. She also developed brain metastasis, for which 
whole-brain radiation therapy was performed. Ten years and 9 months after surgery, the patient died 
(1 year and 2 months after the onset of cardiac tamponade). 
Discussion 
Carcinomatous pericarditis is observed in 10–20% of patients with malignancies, 
and the common cancers are lung cancer, breast cancer, leukemia and malignant 
lymphoma. Carcinomatous pericarditis is detected at autopsy in 10–20% of breast 
cancer patients, although the prevalence of this condition during the clinical course is 
relatively low at 6.1% [4, 5]. Cardiac tamponade is a life-threatening condition 
requiring prompt diagnosis and treatment. 
Subjective symptoms characterized by dyspnea and cough are useful for making an 
early diagnosis of cardiac tamponade. In addition, the characteristic physical findings 
include paradoxical pulse, carotid distention, edema and decreased heart sounds. Heart 
enlargement and pleural effusion are seen on chest X-ray and decreased voltage and 
tachycardia on electrocardiography. In particular, echocardiography is a simple and 
useful diagnostic tool that allows a definitive diagnosis of pericardial effusion, right 
heart collapse and decreased wall motion. Pericardial effusion is caused by a variety of 
conditions including carcinomatous pericarditis, drug therapy with molecular targeting 
agents or anticancer drugs, radiation therapy, inflammation and so on. Although 
cardiac dysfunction caused by molecular targeting agents is usually reversible and 
often resolves after cessation of administration [6], carcinomatous pericarditis requires 
aggressive treatment. Pericardial fluid cytology is useful in the differential diagnosis of 
carcinomatous pericarditis with a reported sensitivity of 90% [7]. In addition, 
coexisting carcinomatous pleurisy or lung metastasis is observed in 63–100% of 
patients, so physicians should be alert to the possible presence of such conditions [8].  
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Treatments of cardiac tamponade include ‘pericardiocentesis and intrapericardial 
instillation’ and ‘pericardial window’, and no difference in recurrence rates between 
the two methods has been reported [9]. Pericardiocentesis and intrapericardial 
instillation is the first choice because of safety and wide availability. Pericardial 
window should be considered when the condition is intractable. According to Arao et 
al. [10], indications for this treatment are heart failure symptoms such as severe 
orthopnea and dyspnea (NYHA class III or IV) and echo-free space of at least 1 cm 
observed during the diastolic phase, which ensures the safety of the centesis procedure. 
Intrapericardial instillation is regarded as an important part of the treatment because 
the recurrence rate of pericardial effusion approached 70% when only 
pericardiocentesis and drainage were performed [11]. The complications of 
intrapericardial instillation include chest pain, pyrexia, inflammation and constrictive 
pericarditis. Bleomycin, mitomycin C, CDDP and epirubicin are reportedly effective 
treatments. The European Society of Cardiology guidelines has recommended the use of 
thiotepa for the treatment of carcinomatous pericarditis in breast cancer patients [12]. 
Bischiniotis et al. [13] recommended the use of CDDP for the following: (1) no cardiac 
toxicity; (2) no pain or hematological toxicity, owing to lower absorption from the 
pericardium, and (3) no occurrence of constrictive pericarditis. Thus, we chose CDDP in 
the present 3 patients. 
Table 1 shows 13 additional cases of cardiac tamponade encountered in our 
hospital. All 13 patients had recurrent carcinomas. HER2 overexpression was observed 
in 1 of 10 (10%) patients. Trastuzumab was not used in any of these patients, and none 
of the patients presented with congestive heart failure symptoms associated with the 
use of molecular targeting agents. The average time period between the first 
recurrence and the diagnosis of pericardial effusion was 34.7 months (range 3–90). 
Many patients had been treated with anticancer drugs for a prolonged period, so 
differential diagnosis from drug-induced heart failure was required. Pericardial fluid 
cytology was performed in 12 patients, and 10 patients were diagnosed with 
carcinomatous pericarditis. The remaining patients were also strongly suspected of 
having carcinomatous pericarditis based on their clinical courses and the presence of 
bloody pericardial fluid. 
The procedure of pericardiocentesis and intrapericardial instillation employed in 
our hospital is shown in fig. 2. We perform pericardiocentesis under ultrasonic 
guidance using a subxiphoid approach or an intercostal approach. The complications of 
pericardiocentesis include ventricular perforation, ventricular arrhythmia and 
pneumothorax. Thus, this procedure must be performed by a sufficiently trained 
doctor. Intrapericardial instillation should be administered after the pericardial 
effusion has been drained in patients with carcinomatous pericarditis confirmed by 
cytology. CDDP was used for 11 of the reviewed patients, and CDDP + OK-432 for the 
other 2 patients. In most of these cases, pericardial effusion was markedly reduced 
after drug administration and the drainage tubes were subsequently removed. When 
the pericardial effusion was not reduced by treatment, drug administration was 
repeated. No recurrence of pericardial effusion was observed in 11 patients (85%) after 
the initial local treatment. In the remaining 2 patients who showed recurrence of 
pericardial effusion, repeat treatment with the same drug was effective. Therefore, 
pericardiocentesis and intrapericardial instillation of CDDP were considered to be 
effective for local control.  
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Cardiac tamponade as the initial manifestation of recurrence of breast cancer is rare 
[8]. This condition is occasionally observed in patients with aggravation of recurrent 
breast cancer. For the 13 patients reviewed herein, the median survival time after the 
onset of cardiac tamponade was only 4 months (fig. 3). Eight patients (62%) died 
within 6 months, and 6 of the 8 patients showed no improvements in ADL after local 
control. These 6 patients were considered to be in the end stage of breast cancer at the 
time they developed carcinomatous pericarditis. On the other hand, there are a few 
case reports of long-term survival after local treatment [14]. All 3 patients in the 
present study survived more than 1 year after the onset of cardiac tamponade and also 
showed improvements in ADL after receiving local treatment. They were able to 
receive systemic drug treatment: irinotecan in case 1, exemestane and capecitabine in 
case 2, and capecitabine in case 3. It is difficult to predict outcomes at the time of 
cardiac tamponade onset because general conditions are poor due to acute heart failure 
symptoms. However, for the cases whose distant metastases are controlled by drug 
treatment, local treatment not only leads to the relief of symptoms but also makes it 
possible to conduct subsequent systemic therapy and prolong survival time. 
Conclusion 
Pericardiocentesis and intrapericardial instillation of CDDP are considered to be 
effective local treatments for cardiac tamponade due to carcinomatous pericarditis. We 
have described 3 breast cancer patients with cardiac tamponade who showed 
improvements in ADL after local treatment and achieved long-term survival with 
subsequent systemic treatment. 
 
 
 
Table 1. Cases of malignant effusion in breast cancer 
                                                Case  Age  ER  PgR  HER2  Pericardial effusion    Intrapericardial  
sclerosis 
Improve- 
ment of 
ADL 
Recurrence  
of 
pericardial 
effusion 
Systemic 
therapy 
after 
tamponade  
Survival 
time after 
tamponade 
months 
    characteristic cytology   
                                                    01  68  +  +  –  bloody  class V    CDDP 10 mg  +  –  +  13 
02  46  +  +  –  bloody  class V    CDDP 10 mg  +  –  +  31 
03  46  +  +  –  –  class IIIb   CDDP 10 mg  +  –  +  14 
04  33  –  +  unknown  bloody  class V    CDDP 10 mg  –  +  –  03 
05  61  +  +  unknown  bloody  class V    CDDP 10 mg + 
OK-432 5KE 
–  –  –  01 
06  54  –  –  +  bloody  class V    CDDP 10 mg + 
OK-432 5KE 
–  –  –  01 
07  54  +  +  unknown  bloody  unknown    CDDP 10 mg  +  –  +  04 
08  51  –  –  –  bloody  class V    CDDP 10 mg  –  –  –  01 
09  46  +  +  –  bloody  class V    CDDP 20 mg  +  +  +  08 
10  51  –  –  –  serous  class IIa    CDDP 20 mg  –  –  –  05 
11  56  +  +  –  bloody  class V    CDDP 10 mg  –  –  –  07 
12  60  +  +  –  bloody  class V    CDDP 10 mg  +  –  –  04 
13  74  +  –  –  bloody  class V    CDDP 10 mg  –  –  –  01 
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Fig. 1. a Chest X-ray showing enlarged cardiac silhouette. b CT scan showing pericardial effusion and 
pleural effusion. c Echocardiogram showing pericardial effusion and right ventricular collapse. 
 
 
 
 
 
 
Fig. 2. Method of treatment for malignant pericardial effusion. 
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Fig. 3. Overall survival rate of malignant pericardial effusion in breast cancer. 
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